Kim Jong B, O'Hare Michael J, Stein Robert
Department of Surgery, Ludwig Institute for Cancer Research/University College London Breast Cancer Laboratory, Royal Free and University College London Medical School, London, UK.
Breast Cancer Res. 2004;6(1):22-30. doi: 10.1186/bcr645. Epub 2003 Aug 19.
Survival rates of patients with early breast cancer in the United Kingdom and in the United States have improved steadily over the past 15 years. The only way to continue or even accelerate this progress, however, is the discovery and development of new preventative and therapeutic strategies. With the massive explosion in potential therapeutic strategies becoming available, in the postgenomic era, better and more representative breast cancer models are urgently required for preclinical trials. Development of better in vivo models of human breast cancer are thus of crucial importance in the development of new cancer therapeutics.
在过去15年里,英国和美国早期乳腺癌患者的生存率稳步提高。然而,要继续甚至加速这一进展,唯一的方法是发现和开发新的预防和治疗策略。在后基因组时代,随着大量潜在治疗策略的涌现,临床前试验迫切需要更好、更具代表性的乳腺癌模型。因此,开发更好的人乳腺癌体内模型对于新型癌症治疗方法的研发至关重要。